#ELI LILLY $LLY back to ATH! What's next for LLY (Long term).
Eli Lilly (LLY) stock jumped more than 3% to a record high on Tuesday after clinical trial results showed tirzepatide—the active ingredient in Lilly's injectable weight-loss drug Zepbound and diabetes treatment Mounjaro—lowered patients' risk of developing type 2 diabetes by 94%.
LLY is climbing back toward its record high of 966.10 reached on July 15.
The three-year study of patients with prediabetes and either obesity or overweight also found that those who received tirzepatide lost 22.9% of their body weight on average, compared with 2.1% for patients treated with a placebo.
Eli Lilly shares jumped to an all-time high on Tuesday, bringing their year-to-date return to more than 60%.
This is very bullish news for LLY. This is easily a 1k stock and a good long term investment if you want exposure to the Glucagon-like peptide-1 meds (GLP-1). LLY is number one in that field hands down.
Consensus around 100bn, current 950.
Research material for you:
Alzheimer's potential benefits.
Novo data (NVO), 2025.
LLY is climbing back toward its record high of 966.10 reached on July 15.
The three-year study of patients with prediabetes and either obesity or overweight also found that those who received tirzepatide lost 22.9% of their body weight on average, compared with 2.1% for patients treated with a placebo.
Eli Lilly shares jumped to an all-time high on Tuesday, bringing their year-to-date return to more than 60%.
This is very bullish news for LLY. This is easily a 1k stock and a good long term investment if you want exposure to the Glucagon-like peptide-1 meds (GLP-1). LLY is number one in that field hands down.
Consensus around 100bn, current 950.
Research material for you:
Alzheimer's potential benefits.
Novo data (NVO), 2025.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.